Activity of gefitinib in central nervous system metastases in patients with non-small-cell lung center: Two case reports and a review of the literature

Clinical Lung Cancer

Volumn 7, Issue 2, 2005, Pages 138-140

  Gurpide, Alfonso ^a   Perez Gracia, Jose Luis ^a   Lopez Picazo, Jose Maria ^a   Moreno, Marta ^a   Zubieta, Jose Luis ^a   Martin Algarra, Salvador ^a   Garcia Foncillas, Jesus ^a  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

Adenocarcinoma; Response; Tyrosine kinase inhibitors

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER PATIENT; CASE REPORT; CENTRAL NERVOUS SYSTEM METASTASIS; DRUG EFFICACY; DRUG RESPONSE; DRUG TARGETING; DRUG TOLERABILITY; FEMALE; HISTOPATHOLOGY; HUMAN; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MEDICAL LITERATURE; RETROSPECTIVE STUDY;

EID: 32044438460     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2005.n.030     Document Type: Article

References (15)

1. Ceresoli GL, Cappuzzo F, Gregorc V, et al. Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial. Ann Oncol 2004; 15: 1042-1047.
2. Villano JL, Mauer AM, Vokes EE. A case study documenting the anticancer activity of ZD1839 (Iressa) in the brain. Ann Oncol 2003; 14:656-658.
3. Cappuzzo F, Ardizzoni A, Soto-Parra H, et al. Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC). Lung Cancer 2003; 41:227-231.
4. Cappuzzo F, Calandri C, Battolini S, et al. ZD 1839 in patients with brain metastases from non-small-cell lung cancer (NSCLC): report of four cases. Br J Cancer 2003; 89:246-247.
5. Fujiwara K, Kiura K, Ueoka H, et al. Dramatic effect of ZD1839 ('Iressa') in a patient with advanced non-small-cell lung cancer and poor performance status. Lung Cancer 2003; 40:73-76.
6. Bianco AR, Damianov V, Matano R, et al. Gefitinib ('Iressa', ZD1839) in patients with pretreated stage IIIB-IV non-small-cell lung cancer entering the Iressa' Expanded Access programme at the University Federico II, Naples. Br J Cancer 2003; 89(suppl 2):S26.
7. Diaz-Cantón E. Efficacy of gefitinib (Iressa', ZD1839) in non-small-cell lung cancer metastatic to the brain. Br J Cancer 2003; 89(suppl 2):S28.
8. Maione P, Musto L, Rossi A, et al. Complete response of brain metastases from lung adenocarcinoma with gefitinib ('Iressa', ZD1839). Br J Cancer 2003; 89(suppl 2):S30.
9. Roggero ER, Busi G, Pedrazzini A. Good response in primary tumour, brain, cerebellar and liver metastasis after 2 months' gefitinib ('Iressa', ZD1839) treatment. Br J Cancer 2003; 89(suppl 2):S33.
10. Knuti KA, Wharton RH, Wharton KL, et al. Living as a cancer surpriser: a doctor tells his story. Oncologist 2003; 8:108-122.
11. Takahashi H, Ohrui T, Ebihara S, et al. Effect of gefitinib (ZD1839) on metastatic brain tumour. Lung Cancer 2004; 43:371-372.
12. Hotta K, Kiura K, Ueoka H, et al. Effect of gefitinib ('Iressa', ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer. Lung Cancer 2004; 46:255-261.
13. Ceresoli GL, Gregorc V, Cappuzzo F, et al. ZD1839 n non-small cell lung cancer (NSCLC) patients with brain metastases (BM). Proc Am Soc Clin Oncol 2003; 22:674 (Abstract #2709).
14. Pino MS, Gelibter A, Ceribelli A, et al. Results from compassionate use of gefitinib (Iressa) in progressive pretreated non small cell lung cancer (NSCLC): our experience. Lung Cancer 2003; 41(suppl 2):S250-S251 (Abstract #P-627).
15. Chiu CH, Tsai CM, Chiang SC, et al. Effect of ZD1839 (Iressa) on metastatic brain lesions in patients with advanced non-small cell lung cancer. Lung Cancer 2003; 41(suppl 2):S250-S251 (Abstract #P-631).